Skip to main content
Top
Published in: Clinical Rheumatology 7/2018

01-07-2018 | Editorial

Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”

Authors: Matteo Megna, Anna Balato, Maddalena Napolitano, Lucia Gallo, Francesco Caso, Luisa Costa, Nicola Balato, Raffaele Scarpa

Published in: Clinical Rheumatology | Issue 7/2018

Login to get access

Excerpt

Rheumatology is the branch of medicine dealing with the diagnosis and treatment of articular and connective tissue diseases. Outstanding progresses have been done in the last few decades regarding diseases pathogenesis and new diagnostic processes as well as innovative therapies [1]. Indubitably, the evolution in psoriatic arthritis (PsA) knowledge represents an emblematic example [2]. Indeed, fundamental advances in understanding PsA pathogenesis and natural history have deeply changed its perception by both patients and physicians [3]. In the past, psoriasis was considered just a mere esthetic concern due to a primary defect in keratinocytes, leading to their hyper-proliferation. Nowadays, it is well known that psoriasis and PsA have to be considered a systemic disease, not limited to the skin and joints, but linked to increased cardiovascular risk, obesity, and metabolic syndrome through a shared chronic pro-inflammatory background, establishing the concept of psoriatic disease (PsD) [4]. PsD often requires a multidisciplinary approach through the collaboration of dermatologist, rheumatologist, immunologist, etc. [5]. In addition, being a chronic inflammatory multifactorial disease and dysregulation of immune cells (Th1 and Th17 above all) have been reported as key features of PsD pathogenesis [6]. In this context, a major role is played by inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-17, IL-22, and IL-23 [6, 7]. Advances in PsD pathogenesis have put the basis for the development of new effective drugs for its treatment. Particularly, monoclonal antibody and fusion protein able to inhibit the effects of pro-inflammatory cytokines involved in PsD development, the so-called biologic drugs, have completely revolutionized disease management [8]. It is relevant, for example, that 40 years ago topical treatments such as corticosteroid, salicylic acid, and coal tar represented the main stay of psoriasis therapies, whereas nowadays different new systemic drugs are available such as biologics like anti-TNF-α (adalimumab, etanercept, golimumab, certolizumab, infliximab), anti-IL-12–23 (ustekinumab), and anti-IL-17 (ixekizumab, secukinumab) [810]. Moreover, literature is constantly enriching of clinical trials and surveys regarding newer biologic drugs which will be soon available for psoriasis and PsA treatment such as anti-IL-17 receptor (brodalumab) [11], anti-IL-23 (guselkumab, tildrakizumab) [12, 13], and anti-CD6 (itolizumab) [14]. However, PsD treatment scenario is going to become more and more complex and wide apart from the development of biologic drugs. A new era will be introduced by the so-called small molecules which are able to act at the basis of the pro-inflammatory cascade which dominates PsD pathogenesis, preventing the production of inflammatory cytokines. This is the case of molecules such as phosphodiesterase 4 (PDE4) inhibitor (apremilast) and Janus kinase (JAK) inhibitor (tofacitinib) [15]. …
Literature
1.
go back to reference Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L (2016) Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol 35:1893–1901CrossRefPubMed Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L (2016) Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol 35:1893–1901CrossRefPubMed
2.
go back to reference Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–715CrossRefPubMed Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–715CrossRefPubMed
3.
go back to reference Fiocco U, Stramare R, Coran A, Grisan E, Scagliori E, Caso F, Costa L, Lunardi F, Oliviero F, Bianchi FC, Scanu A, Martini V, Boso D, Beltrame V, Vezzù M, Cozzi L, Scarpa R, Sacerdoti D, Punzi L, Doria A, Calabrese F, Rubaltelli L (2015) Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clin Rheumatol 34:1903–1912CrossRefPubMed Fiocco U, Stramare R, Coran A, Grisan E, Scagliori E, Caso F, Costa L, Lunardi F, Oliviero F, Bianchi FC, Scanu A, Martini V, Boso D, Beltrame V, Vezzù M, Cozzi L, Scarpa R, Sacerdoti D, Punzi L, Doria A, Calabrese F, Rubaltelli L (2015) Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clin Rheumatol 34:1903–1912CrossRefPubMed
4.
go back to reference Caso F, Del Puente A, Oliviero F, Peluso R, Girolimetto N, Bottiglieri P, Foglia F, Benigno C, Tasso M, Punzi L, Scarpa R, Costa L (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol 37:579–586CrossRefPubMed Caso F, Del Puente A, Oliviero F, Peluso R, Girolimetto N, Bottiglieri P, Foglia F, Benigno C, Tasso M, Punzi L, Scarpa R, Costa L (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol 37:579–586CrossRefPubMed
5.
go back to reference Lapadula G, Marchesoni A, Salaffi F, Ramonda R, Salvarani C, Punzi L, Costa L, Caso F, Simone D, Baiocchi G, Scioscia C, Di Carlo M, Scarpa R, Ferraccioli G (2016) Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic arthritis (IDEA). Reumatismo 68:126–136CrossRefPubMed Lapadula G, Marchesoni A, Salaffi F, Ramonda R, Salvarani C, Punzi L, Costa L, Caso F, Simone D, Baiocchi G, Scioscia C, Di Carlo M, Scarpa R, Ferraccioli G (2016) Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic arthritis (IDEA). Reumatismo 68:126–136CrossRefPubMed
6.
go back to reference Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, Scanu A, Facco M, Boso D, Gatto M, Felicetti M, Frallonardo P, Ramonda R, Piva L, Zambello R, Agostini C, Scarpa R, Basso G, Semenzato G, Dayer JM, Punzi L, Doria A (2015) Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol 34:1571–1580CrossRefPubMed Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, Scanu A, Facco M, Boso D, Gatto M, Felicetti M, Frallonardo P, Ramonda R, Piva L, Zambello R, Agostini C, Scarpa R, Basso G, Semenzato G, Dayer JM, Punzi L, Doria A (2015) Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol 34:1571–1580CrossRefPubMed
7.
go back to reference Balato A, Schiattarella M, Di Caprio R, Lembo S, Mattii M, Balato N, Ayala F (2014) Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol 28:1016–1024CrossRefPubMed Balato A, Schiattarella M, Di Caprio R, Lembo S, Mattii M, Balato N, Ayala F (2014) Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol 28:1016–1024CrossRefPubMed
8.
go back to reference Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12:315–331CrossRefPubMed Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12:315–331CrossRefPubMed
9.
go back to reference (1977) The hazardous jungle of topical steroids. Lancet 2:487–8 (1977) The hazardous jungle of topical steroids. Lancet 2:487–8
10.
go back to reference Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A, Scarpa R, Costa L (2016) Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs 21:69–79CrossRefPubMed Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A, Scarpa R, Costa L (2016) Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs 21:69–79CrossRefPubMed
11.
go back to reference Nakagawa H, Niiro H, Ootaki K, Japanese brodalumab study group (2016) Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase I randomized controlled study. J Dermatol Sci 81:44–52CrossRefPubMed Nakagawa H, Niiro H, Ootaki K, Japanese brodalumab study group (2016) Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase I randomized controlled study. J Dermatol Sci 81:44–52CrossRefPubMed
13.
go back to reference Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R (2015) Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol 173:930–939CrossRefPubMed Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R (2015) Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol 173:930–939CrossRefPubMed
14.
go back to reference Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR, Bhat R, Shetty N, Manmohan G, Sai Krishna K, Padmaja D, Pratap DV, Garg V, Gupta S, Pandey N, Khopkar U, Montero E, Ramakrishnan MS, Nair P, Ganapathi PC (2014) Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 71:484–492CrossRefPubMed Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR, Bhat R, Shetty N, Manmohan G, Sai Krishna K, Padmaja D, Pratap DV, Garg V, Gupta S, Pandey N, Khopkar U, Montero E, Ramakrishnan MS, Nair P, Ganapathi PC (2014) Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 71:484–492CrossRefPubMed
15.
go back to reference Costa L, Del Puente A, Peluso R, Tasso M, Caso P, Chimenti MS, Sabbatino V, Girolimetto N, Benigno C, Bertolini N, Del Puente A, Perricone R, Scarpa R, Caso F (2017) Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother 18:1557–1567CrossRefPubMed Costa L, Del Puente A, Peluso R, Tasso M, Caso P, Chimenti MS, Sabbatino V, Girolimetto N, Benigno C, Bertolini N, Del Puente A, Perricone R, Scarpa R, Caso F (2017) Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother 18:1557–1567CrossRefPubMed
16.
go back to reference Castro A, Jerez MJ, Gil C, Martinez A (2005) Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 25:229–244CrossRefPubMed Castro A, Jerez MJ, Gil C, Martinez A (2005) Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 25:229–244CrossRefPubMed
17.
go back to reference Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, Piva L, Molena B, Caso F, Costa L, Scanu A, Pagnin E, Atteno M, Scarpa R, Basso G, Semenzato G, Punzi L, Doria A, Dayer JM (2014) JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 58:61–69CrossRefPubMed Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, Piva L, Molena B, Caso F, Costa L, Scanu A, Pagnin E, Atteno M, Scarpa R, Basso G, Semenzato G, Punzi L, Doria A, Dayer JM (2014) JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 58:61–69CrossRefPubMed
18.
go back to reference Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 74:134–142CrossRefPubMed Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 74:134–142CrossRefPubMed
19.
go back to reference Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156–3167CrossRefPubMed Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156–3167CrossRefPubMed
20.
go back to reference Krueger J, Clark JD, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O'Neil SP, Reddy PS, Tatulych S, A3921147 Study I (2016) Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol 137:1079–1090 Krueger J, Clark JD, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O'Neil SP, Reddy PS, Tatulych S, A3921147 Study I (2016) Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol 137:1079–1090
21.
go back to reference Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525–1536CrossRefPubMed Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525–1536CrossRefPubMed
22.
go back to reference Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301CrossRefPubMed Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301CrossRefPubMed
24.
go back to reference Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, Bottiglieri P, Scarpa R, Caso F (2017) Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D 17:509–522CrossRefPubMedPubMedCentral Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, Bottiglieri P, Scarpa R, Caso F (2017) Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D 17:509–522CrossRefPubMedPubMedCentral
25.
go back to reference Alwan W, Nestle FO (2015) Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 33:S2–S6PubMed Alwan W, Nestle FO (2015) Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 33:S2–S6PubMed
26.
go back to reference Foulkes AC, Warren RB (2015) Pharmacogenomics and the resulting impact on psoriasis therapies. Dermatol Clin 33:149–160CrossRefPubMed Foulkes AC, Warren RB (2015) Pharmacogenomics and the resulting impact on psoriasis therapies. Dermatol Clin 33:149–160CrossRefPubMed
27.
28.
go back to reference Scarpa R, Caso F (2018) Spondyloarthritis: which composite measures to use in psoriatic arthritis? Nat Rev Rheumatol 14:125–126CrossRefPubMed Scarpa R, Caso F (2018) Spondyloarthritis: which composite measures to use in psoriatic arthritis? Nat Rev Rheumatol 14:125–126CrossRefPubMed
29.
go back to reference Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33:833–839PubMed Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33:833–839PubMed
30.
go back to reference Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. Springerplus 3:759CrossRefPubMedPubMedCentral Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. Springerplus 3:759CrossRefPubMedPubMedCentral
Metadata
Title
Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”
Authors
Matteo Megna
Anna Balato
Maddalena Napolitano
Lucia Gallo
Francesco Caso
Luisa Costa
Nicola Balato
Raffaele Scarpa
Publication date
01-07-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 7/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4090-6

Other articles of this Issue 7/2018

Clinical Rheumatology 7/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.